



Universiteit  
Leiden  
The Netherlands

## **Huntington's disease : hypothalamic, endocrine and metabolic aspects**

Aziz, N.A.

### **Citation**

Aziz, N. A. (2010, March 31). *Huntington's disease : hypothalamic, endocrine and metabolic aspects*. Retrieved from <https://hdl.handle.net/1887/15183>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/15183>

**Note:** To cite this publication please use the final published version (if applicable).

## Hypocretin and melanin-concentrating hormone in patients with Huntington's disease

Ahmad Aziz<sup>1,4</sup>, MSc; Rolf Fronczek<sup>1,4</sup>, MSc; Marion Maat-Schieman<sup>1</sup>, MD, PhD; Unga Unmehopa<sup>4</sup>, BSc; Freek Roelandse<sup>2</sup>; Sebastiaan Overeem<sup>1,5</sup>, MD, PhD; Sjoerd van Duinen<sup>3</sup>, MD, PhD; Gert-Jan Lammers<sup>1</sup>, MD, PhD; Dick Swaab<sup>4</sup>, MD, PhD; Raymund Roos<sup>1</sup>, MD, PhD

*Brain Pathol (2008); 18(4): 474-483*

<sup>1</sup> Departments of Neurology, <sup>2</sup> Clinical Chemistry and <sup>3</sup>Pathology, Leiden University Medical Centre, Leiden, the Netherlands

<sup>4</sup> Netherlands Institute for Neuroscience, Amsterdam ZO, the Netherlands

<sup>5</sup> Department of Neurology, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands

## ABSTRACT

To evaluate whether hypocretin-1 (orexin-A) and melanin-concentrating hormone (MCH) neurotransmission are affected in patients with Huntington's disease (HD), we immunohistochemically stained hypocretin and MCH neurons and estimated their total numbers in the lateral hypothalamus of both HD patients and matched controls. In addition, hypocretin-1 levels were determined in prefrontal cortical tissue and post-mortem ventricular cerebrospinal fluid (CSF) using a radioimmunoassay. The total number of hypocretin-1 neurons was significantly reduced by 30% in HD brains ( $p=0.015$ ), while the total number of MCH neurons was not significantly altered ( $p=0.100$ ). Levels of hypocretin-1 were 33% lower in the prefrontal cortex of HD patients ( $p=0.025$ ), but ventricular CSF levels were similar to control values ( $p=0.306$ ). Neuronal intranuclear and cytoplasmic inclusions of mutant huntingtin were present in all HD hypothalami, although with a variable distribution across different hypothalamic structures. We found a specific reduction in hypocretin signalling in patients with HD as MCH cell number was not significantly affected. It remains to be shown whether the moderate decrease in hypocretin neurotransmission could contribute to clinical symptoms. As the number of MCH expressing neurons was not affected, alterations in MCH signalling are unlikely to have clinical effects in HD patients.

Huntington's disease (HD) is an autosomal dominant progressive neurodegenerative disorder caused by an expanded CAG trinucleotide repeat in the *IT15* gene on chromosome 4. Choreiform movements, psychiatric and behavioural problems and cognitive impairment characterize HD.<sup>16</sup> Other debilitating but less well-known features of the disease are weight loss, sleep disturbances and autonomic nervous system dysfunction,<sup>2</sup> the causes of which are poorly understood. HD is neuropathologically characterized by generalized atrophy and cell death in the striatum and cerebral cortex and the presence of neuronal intranuclear and cytoplasmic inclusions of mutant huntingtin, particularly in the neocortex and neostriatum.<sup>8,41</sup> Substantial hypothalamic atrophy and cell death have also been reported,<sup>18,20,21</sup> however, the presence of HD inclusions has not been investigated so far in different hypothalamic structures.

Hypocretin/orexin and melanin-concentrating hormone (MCH) are neuropeptides that are synthesized in the lateral hypothalamus by two distinct neuronal populations.<sup>30,31,36</sup> These neuropeptides both play a key role in the regulation of body energy metabolism, sleep-wake cycles and autonomic functions.<sup>17,30,33,43</sup> Moreover, recent animal studies implicate the MCH system in the modulation of several behavioural modalities, most notably stress, depression and sexual behaviour.<sup>30,34</sup> A relation has also been demonstrated between hypocretin release and some psychiatric symptoms.<sup>5,32</sup> Potential alterations in hypocretin and/or MCH signalling might thus contribute to some symptoms in HD patients, particularly weight loss, sleep disturbances and autonomic dysfunction as well as some behavioural disorders like increased rates of depression and anxiety in these subjects.<sup>16</sup>

Recently, it was demonstrated that the R6/2 mouse, the most widely used model of HD that expresses the first exon of the *HD* gene with ~150 CAG repeats, exhibits a progressive and massive loss of hypocretin-1 immunopositive neurons in the lateral hypothalamic area.<sup>27</sup> This loss amounted to 71% at the end stage (12 weeks) and was accompanied by loss of neuronal nuclear antigen (NeuN)-immunopositive neurons.<sup>27</sup> On the other hand, the YAC128 mouse model of HD with the full-length mutant *HD* gene with ~120 CAG repeats, shows a 10% loss of hypocretin-1 immunopositive neurons at 12 months.<sup>4</sup> Furthermore, MCH cell number was reported to be decreased by 38% in the hypothalamus of twelve week old R6/2 mice, while MCH peptide levels were reduced by 57%.<sup>39</sup> Atrophy and a decreased density of hypocretin-1 expressing neurons in single coronal sections from the lateral hypothalamus have also been observed in HD patients.<sup>27</sup> Nevertheless, four recent papers reported normal hypocretin-1 concentrations in the cerebrospinal fluid (CSF) of HD patients.<sup>3,4,11,24</sup>

In order to validate and extend the above findings in patients with HD we applied a four-way approach. First, we estimated the total numbers of both hypocretin-1 and MCH expressing neurons in the lateral hypothalamus of HD patients and matched controls. This allowed testing for the specificity of potential changes in the neuronal numbers. Second, we measured hypocretin-1 levels in post-mortem ventricular CSF because this could better reflect hypocretin-1 production than spinal measurements.<sup>7,10</sup> Third, hypocretin-1 contents in peptide extracts from cerebral cortex were assessed, since this has been shown to be a more sensitive technique compared to CSF measurements.<sup>10,28</sup> And finally, we also investigated various hypothalamic regions, including the lateral hypothalamus, for the presence of neuronal intranuclear and cytoplasmic inclusions.

## MATERIALS AND METHODS

### *Post-mortem material*

Autopsy hypothalami from eight HD patients and eight controls (matched for age, sex, post-mortem delay and fixation time) were obtained through the Netherlands Brain Bank (NBB). Ventricular CSF was available in 7 of these HD patients and one of the controls; therefore CSF from six additional controls (matched for age, sex and post-mortem delay) was used for comparison (Table 1). Frozen prefrontal cortical tissue from a second group of 19 HD patients and 16 controls was obtained through the Leiden University Medical Centre HD pathology archives (Table 2). HD brains were graded according to the scheme of Vonsattel et al. for neuropathological disease severity.<sup>41</sup> All HD patients had clinical features and a positive family history of the disease; one patient (#1; Table 2) had infantile HD and was studied separately as there are indications that infantile and classical HD may differ neuropathologically.<sup>35</sup> The diagnosis of HD was genetically confirmed (i.e. CAG repeat lengths  $\geq 40$ ) in all but one of these patients (#HD-8, Table 1). However, the latter patient's brain showed HD pathology grade II and the presence of neuronal intranuclear and cytoplasmic inclusions combined with a positive family history of the disease further consolidated the diagnosis. Exclusion criteria for control subjects were primary neurological and/or psychiatric disorders and glucocorticoid therapy during the final premortal illness period, except two controls who had suffered strokes and were used for prefrontal cortex hypocretin-1 measurements (#C-4 and #C-14; Table 2).

### *Hypocretin-1 and MCH immunohistochemistry*

The hypothalami were fixed in 10% PBS (pH 7.4) formalin at room temperature and were paraffin embedded and serially sectioned at 6  $\mu\text{m}$  in rostral-caudal direction. Every 100<sup>th</sup> section was stained with thionin for orientation. The lateral hypothalamus, from the level where the fornix abuts the paraventricular nucleus up to the posterior border of the corpora mamillaria, was stained at 600  $\mu\text{m}$  intervals in every two consecutive sections. One of the sections was stained with a hypocretin-1 and the other with a MCH monoclonal antibody (Phoenix Pharmaceuticals, Inc., Belmont, CA; catalog no. H-003-30 and H-070-47, respectively). The sections were visualized according to the avidin-biotin complex method using diaminobenzidine-nickel solution to finish the staining as described previously.<sup>13</sup>

### *N-terminal huntingtin immunohistochemistry*

Using thionin staining for orientation, nine to ten sections were chosen so that large parts of the following hypothalamic (and adjacent) structures would be contained in at least two coronal cuts: the suprachiasmatic nucleus, the supraoptic nucleus, the paraventricular nucleus, the infundibular nucleus, the diagonal band of Broca, the nucleus basalis of Meynert, the ventromedial nucleus, the dorsomedial nucleus, the lateral hypothalamus/perifornical area, the tuberomammillary nucleus, the lateral tuberal nucleus and the supramammillary area (the supramammillary area was contained in only one coronal cut). These sections were stained with a monoclonal antibody against the N-terminus of human huntingtin (Chemicon, Temecula, CA; batch no. 5374) after pretreatment by boiling in citrate buffer (pH 6.0) for 20 minutes. The sections were processed according to the avidin-biotin complex method using diaminobenzidine-nickel solution and counterstained with Harris's Hematoxylin for nuclear staining.

### *Antibody specificity*

The specificity of the hypocretin-1 antibody has been confirmed previously.<sup>9</sup> To test the specificity of

**Table 1. Clinicopathological details of HD patients and control subjects.**

		Sex	Age (yrs)	Age of onset (yrs)	PMD (h)	Fix (d)	Brain weight (g)	Grade	CAG repeat length	Cause of death	MCH cell no.	Hert-1 cell no.	Hert-1 levels in CSF (pg/ml)
<b>Patients</b>	HD-1	M	57	42	07:30	53	1162	3-4	46	Cachexia	76987	42088	536
	HD-2	F	50	35	05:40	55	1292	2-3	47	Pneumonia	N.A.	24022	595
	HD-3	M	79	54	06:15	34	1001	4	44	Pneumonia and sepsis	75652	29890	422
	HD-4	F	67	56	06:05	41	1289	1	45	Unknown	102436	50863	531
	HD-5	M	49	40	05:45	49	1122	3	54	Cachexia secondary to pneumonia.	N.A.	20448	468
	HD-6	F	80	58	07:15	49	906	2	41	Pneumonia	76620	36023	404
	HD-7	M	61	39	10:25	48	1380	3	43	Pneumonia	77846	27880	481
	HD-8	M	54	41	03:50	80	1212	2	-	Sudden death	N.A.	42569	N.A.
<b>Median</b>			59.0	41.5	6:10	49.0	1187.0	-	45.0		76987	32957	
<b>Percentile</b>													
<b>25<sup>th</sup>:</b>			51.0	39.3	5:41	42.8	1031.3		43.0		76136	24987	
<b>75<sup>th</sup>:</b>			76.0	55.5	7:26	54.5	1291.3		47.0		90141	42449	
<b>Controls</b>	C-1 <sup>a</sup>	M	58	-	<17:00	96	1408	-	-	Aorta dissection	77237	49105	N.A.
	C-2 <sup>a</sup>	F	49	-	<13:30	165	1437	-	-	Metastasized cervix carcinoma.	89347	56250	N.A.
	C-3 <sup>a</sup>	M	79	-	<3:00	53	1435	-	-	Haemorrhage from leaking aorta prosthesis	84652	36231	N.A.
	C-4 <sup>a</sup>	F	68	-	05:45	32	1153	-	-	Unknown	N.A.	52900	N.A.
	C-5 <sup>a</sup>	M	49	-	<12:40	40	1404	-	-	Sudden death	118604	54638	N.A.
	C-6 <sup>a,b</sup>	F	82	-	05:30	36	1280	-	-	Myocardial infarction	N.A.	60972	409
	C-7 <sup>a</sup>	M	61	-	13:50	52	2220	-	-	Carcinoma of the oesophagus	94776	27912	N.A.
	C-8 <sup>a</sup>	M	54	-	<08:00	59	1350	-	-	Hepatocellular carcinoma	86792	53216	N.A.
	C-9 <sup>b</sup>	M	56	-	5:25	-	1522	-	-	Cardiac infarction	N.A.	N.A.	536
	C-10 <sup>b</sup>	F	51	-	7:40	-	1156	-	-	Sepsis	N.A.	N.A.	640
	C-11 <sup>b</sup>	M	79	-	6:00	-	1392	-	-	Mestastasized adenocarcinoma	N.A.	N.A.	631
	C-12 <sup>b</sup>	F	69	-	4:20	-	1186	-	-	Heart failure	N.A.	N.A.	549
	C-13 <sup>b</sup>	M	53	-	14:25	-	1341	-	-	Heart failure	N.A.	N.A.	581
	C-14 <sup>b</sup>	M	61	-	12:05	-	1460	-	-	Heart failure	N.A.	N.A.	336
<b>Group a:</b>													
<b>Median</b>			59.5		10:20	52.5	1406.0				88070	53058	
<b>Percentiles</b>													
<b>25<sup>th</sup>:</b>			50.3		5:33	37.0	1297.5				82798	39450	
<b>75<sup>th</sup>:</b>			76.3		13:45	86.8	1436.5				100733	55847	
<b>Group b:</b>													
<b>Median</b>			61.0		6:00	-	1341.0				-	-	549.0
<b>Percentiles</b>													
<b>25<sup>th</sup>:</b>			53.0		5:25		1186.0						409.0
<b>75<sup>th</sup>:</b>			79.0		12:05		1460.0						631.0

<sup>a</sup>) Hypothalamic material from these controls was available for Hert-1 and/or MCH immunohistochemistry.

<sup>b</sup>) Ventricular CSF from these controls was available for Hert-1 radioimmunoassay.

**Legend:** Fix = fixation time, PMD = post-mortem delay, Grade = Vonsattel et al's grade, N.A. = not available. Hert-1, hypocretin-1.

**Table 2. Clinicopathological data of subjects used for hypocretin brain tissue measurement.**

	subject no.	Age at death	Sex	Grade	CAG	Cause of death	Hcrt-1 tissue content (pg/g)
<b>Infantile HD</b>	1 <sup>a</sup>	19	F	3	86	Cachexia	1097
<b>Adult HD</b>	2	34	M	3	52	Unknown	389
	3	40	F	3	41	Suicide	530
	4	44	M	N.A.	50	Pneumonia	343
	5	45	M	4	53	Recurrent aspiration pneumonia	198
	6	49	M	3	47	Respiratory insufficiency	743
	7	51	M	3	46	Bronchopneumonia	360
	8	51	M	3	45	Unknown	584
	9	53	F	2	47	Pulmonary embolism	511
	10	54	M	3	43	Pneumonia	198
	11	55	F	3	47	Metast. Grawitz tumor	617
	12	57	F	3	43	Pulmonary embolism	278
	13	57	M	4	49	Bronchopneumonia	275
	14	57	M	3	47	Unknown	665
	15	63	F	3	43	Basilar artery thrombosis	1066
	16	66	F	3	41	Squamous cell lung carcinoma	443
	17	69	F	2	42	Aspiration pneumonia	725
	18	75	M	3	43	Unknown	302
	19	77	M	3	39	Bronchopneumonia	376
<b>Median</b>		54.5		3.0	45.5		416.4
<b>Percentiles (25<sup>th</sup> – 75<sup>th</sup>)</b>		48.0 – 63.8		2.5 – 3.0	42.8 – 47.5		295.8 – 629.4
<b>Controls</b>	1	37	M	-	-	Myocardial infarction	996
	2	46	M	-	-	Cardiac arrhythmia	364
	3	48	M	-	-	Myocardial infarction	665
	4	52	M	-	-	Stroke	688
	5	60	F	-	-	Pneumonia	433
	6	63	F	-	-	Leptomeningeal metastasis	737
	7	64	M	-	-	Myocardial infarction	1368
	8	67	F	-	-	Aortic Dissection	858
	9	68	M	-	-	Pneumonia	697
	10	70	M	-	-	Metastasized carcinoma	1282
	11	71	M	-	-	Cardiomyopathy	573
	12	74	M	-	-	Metastasized carcinoma	243
	13	76	M	-	-	Aortic Dissection	638
	14	79	F	-	-	Stroke	892
	15	83	M	-	-	Leptomeningeal metastasis	358
	16	86	M	-	-	Myocardial infarction	570
<b>Median</b>		67.5					676.6
<b>Percentiles (25<sup>th</sup> – 75<sup>th</sup>)</b>		54.0 -75.5					467.5-883.9

<sup>a</sup>) This patient had juvenile HD and was therefore studied separately.

**Legend:** Grade = Vonsattel et al's grade, CAG = CAG repeat length, Hcrt-1, hypocretin-1, N.A. = not available.

the MCH antibody, a dot blot was performed,<sup>40</sup> adding a dilution of 1:1000 anti-MCH onto 2% gelatin-coated nitrocellulose paper (0.1- $\mu$ m pore size) containing different spots with 20 pmol MCH, hypocretin-1, somatostatin (1–14), somatostatin (1–28), galanin, MCH-1 receptor,  $\beta$ -lipotropin, substance-P,  $\alpha$ -melanocyte-stimulating hormone, luteinizing hormone-releasing hormone, adrenocorticotrophic hormone (1–39), neurotensin, oxytocin, corticotropin-releasing hormone, agouti-related protein (83–132), neuropeptide-Y, growth hormone-releasing hormone (1–40), arginine-vasopressin, desacetylmelanocyte-stimulating hormone, neuropeptide EI, glycoprotein hormone receptor and cocaine- and amphetamine-regulated transcript. The next day, the nitrocellulose sheet was incubated with secondary antibody, avidin-biotin peroxidase complex, and diaminobenzidinenickel solution to finish the staining. The only spot that showed staining was the one containing MCH. Specificity was further confirmed by the absence of staining in hypothalamic sections using antiserum preadsorbed with the human MCH peptide fixed overnight with 4% formaldehyde onto gelatin-coated nitrocellulose filter paper, 0.1  $\mu$ m, and the presence of staining when preadsorbed with  $\alpha$ -melanocyte-stimulating hormone peptide, which did not differ from unadsorbed serum.

### ***Quantification of hypocretin-1 and MCH neuronal numbers***

An estimate of the total number of hypocretin-1 and MCH immunoreactive (IR) cells was made using an image analysis system (ImagePro version 4.5, Media Cybernetics, Silver Spring) connected to a camera (JVC KY-F553CCD) and plain objective microscope (Zeiss Axioskop with Plan-NEOFLUAR Zeiss objectives, Carl Zeiss GmbH, Jena, Germany). In every section randomly selected fields, covering in total 15% of a manually outlined area containing all the hypocretin-1 or MCH IR cells, were counted by the same person (NAA) who was blinded to the diagnosis. Each positively stained profile containing a nucleolus was counted.<sup>10</sup> Calculation of the total number of hypocretin-1 IR neurons was performed by a conversion program based upon multiplication of the neuronal counts by sample frequency of the sections as described previously.<sup>14</sup> Mean ( $\pm$  SD) number of sections quantified per subject was  $10.2 \pm 1.5$  for hypocretin-1 and  $11.5 \pm 2.3$  for MCH. The coefficient of variation (i.e. SD / mean  $\times$  100%) of this method was 3.4% for hypocretin-1 and 4.5 % for MCH (calculated by counting one complete control twice).

### ***Hypocretin-1 measurements in cerebral cortex and CSF***

One gram of frozen prefrontal cortex was used for hypocretin-1 measurements (Table 2). The most rostral part of the prefrontal cortex was chosen, as this cortical region is densely innervated by hypocretin neurons resulting in high hypocretin-1 concentrations.<sup>29</sup> The tissue samples were boiled for 10 minutes in 10.0 ml of MilliQ water, cooled to room temperature, acidified using glacial acetic acid and HCl (final concentration: 1.0 M and 20.0 mM respectively), homogenized and centrifuged. The supernatant was acidified again with an equal volume of 0.1% trifluoroacetic acid and vacuum dried. Samples were resuspended in 500  $\mu$ l of radioimmunoassay buffer and centrifuged at 3000 rpm for 10 minutes before measurements. Immediately after collection, ventricular CSF was centrifuged at 2500 rpm for 10 minutes and the supernatant was stored at  $-80^{\circ}\text{C}$  until hypocretin-1 levels were measured using a commercially available radioimmunoassay (Phoenix Pharmaceuticals, Belmont, USA). All measurements were conducted in duplicate 100  $\mu$ l aliquots in a single assay run. The detection limit was 50 pg/ml and intra-assay variability was less than 5%. We used a validated reference sample to adjust levels to previously reported values.<sup>10,28</sup>

### ***Assessment of neuronal intranuclear and cytoplasmic inclusions***



The presence or absence of neuronal intranuclear inclusions and cytoplasmic inclusions (i.e. inclusions in dystrophic neurites) in the hypothalamic regions of interest were assessed by one of us (NAA) at  $\times 100$  magnification.<sup>8</sup> For each region two coronal sections were investigated. The percentage of HD patients who had either neuronal intranuclear or cytoplasmic inclusions of mutant huntingtin was calculated per structure (Table 4).

### **Statistics**

All data are presented as medians (25<sup>th</sup> – 75<sup>th</sup> percentile). Differences between the groups were statistically evaluated by the Mann-Whitney *U* (MWU) test, the Wilcoxon signed rank (WSR) test or the  $\chi^2$ -test. Spearman's  $\rho$  correlation test was performed to assess all correlations. Differences in clock time of death (circular parameter) between controls and patients with HD were tested with the Watson's two-sample test of homogeneity.<sup>23</sup> Tests were two-tailed and values of  $p < 0.05$  were considered to be significant. Local linear regression was used to fit curves to the standardized pooled data (Figure 2).<sup>22</sup>

## **RESULTS**

### ***Hypocretin-1 and MCH neurons in HD patients and controls***

#### *Subject characteristics*

There were no significant differences in age, sex, post-mortem delay, fixation time and clock time of death between the HD and the control group (all  $p \geq 0.27$  (Table 1)).

#### *Distribution of hypocretin-1- and MCH neurons*


The intensity of hypocretin-1 and MCH immunostaining showed no obvious differences between the HD and the control group (Figure 1). Hypocretin-1 IR neurons were restricted to the perifornical region in the lateral hypothalamus as previously described.<sup>9</sup> MCH IR neurons were mainly confined to the same areas although they were more widely disseminated than hypocretin-1 IR neurons. The first hypocretin-1 IR neurons emerged in the lateral hypothalamus at the junction of the fornix and the paraventricular nucleus and were followed by the first MCH IR neurons. However, the rostro-caudal distance between the location of the first hypocretin-1 neurons and that of the first MCH neurons did not significantly differ from zero (either in patients ( $n = 8$ ) or controls ( $n = 8$ ) or both groups combined (respective  $p$ -values by WSR test: 0.168, 0.336 and 0.085)) (Figure 2). At subsequent levels the fornix was surrounded by both hypocretin-1 and MCH IR cell bodies throughout its entire course up to the mamillary bodies. The number of hypocretin-1 IR neurons peaked just before the fornicomamillary junction, whereas the peak number of MCH IR neurons was seen after this junction in the supramamillary area (Figure 2); the rostro-caudal distance between the two peaks was calculated in each individual and was significantly larger than zero (all  $p \leq 0.011$  by WSR test, either in patients (1200  $\mu\text{m}$  [1200-1800]) or controls (1500  $\mu\text{m}$  [1200-2250]), or both groups combined (1200  $\mu\text{m}$  [1200-1800])).

#### *Hypocretin-1 and MCH cell numbers*

The total number of hypocretin-1 IR neurons in the lateral hypothalamus of HD patients was significantly reduced by 30 % compared to values in matched controls (32,957 (24,987 – 42,449) vs. 53,058 (39,450 –

55,847);  $p = 0.015$ ; Figure 3). As the available hypothalamic material of two controls and three HD patient (#C-4, #C-6 and #HD-2, #HD-5 and #HD-8, respectively (Table 1)) did not contain the caudal part of the MCH area, these cases were excluded from subsequent calculations of the total number of MCH IR neurons. Exclusion of these subjects did not alter group comparability. There was a trend towards a decrease in the total number of MCH IR neurons in HD patients (HD: 76,987 (76,136 – 90,141); controls: 88,070 (82,798 – 100,733);  $p = 0.100$ ; Figure 3).

**Figure 1.** Representative photographs of hypocretin-1 and MCH IR neurons in the lateral hypothalamus of two control subjects (A and C, #C-4 and #C-2 respectively) and two patients with HD (B and D, #HD-6 and #HD-1 respectively) with neuronal counts at or around the median (Table 1). The pictures were taken from slides with the highest numbers of immunoreactive neurons. The illustrations show a modest reduction in the number of hypocretin-1 IR neurons in the HD brain (A and B) while the number of MCH IR neurons is not significantly affected (C and D). Scale bar 250  $\mu\text{m}$ .




*Effects of age of onset, CAG repeat length, disease duration and Vonsattel et al's grade on hypocretin-1 and MCH cell numbers in HD*

There was a positive trend for the relation between age of onset of HD (defined as the age at which the clinical diagnosis was first made) and hypocretin-1 IR neuronal numbers ( $r = 0.64$ ,  $p = 0.086$ ), but not MCH neuronal numbers ( $r = 0.21$ ,  $p = 0.645$ ). In HD patients, the total hypocretin-1 and MCH cell numbers were

not significantly associated with either CAG repeat length, duration of illness or Vonsattel et al's grades of neuropathological disease severity (Table 3).<sup>41</sup>

**Figure 2.** Distribution patterns of hypocretin-1 and MCH IR neurons in the lateral hypothalamus of controls and HD patients. In order to present data from all subjects in the same diagrams, the individual distribution patterns were standardized in rostro-caudal direction for the anatomical distance between the point where the fornix abuts the paraventricular nucleus (black arrows; at the level of line 'A' in the upper cartoon) and the fornicomamillary junction (grey arrows; at the level of line 'B' in the upper cartoon). This procedure was performed separately for the control and the HD group. In addition, local linear regression was used to fit curves to the standardized pooled data in order to clarify the underlying distribution patterns (kernel = Gaussian, bandwidth value = 1.0). Note that the overall rostro-caudal dispersion of hypocretin-1 and MCH IR neurons does not appear to be noticeably different between control and HD subjects. Upper cartoon: A schematic sagittal view of the hypothalamus; the paraventricular nucleus and the mamillary bodies are indicated in dark. Lower cartoon: A schematic coronal view of the hypothalamus midway between lines 'A' and 'B' in the upper cartoon; the perifornical area and the lateral hypothalamus are indicated in dark (adapted from (36)). Hcrt-1, hypocretin-1; 3V, third ventricle; Fx, fornix; LH, lateral hypothalamus; DM, dorsomedial nucleus; VM, ventromedial nucleus; TMN, tuberomamillary nucleus; INF, infundibular nucleus; OT, optic tract.



### Ventricular CSF hypocretin-1 content

The two groups were well matched for age, sex and post-mortem delay (all  $p > 0.80$ ) (Table 2). Furthermore, there were no significant correlations between these variables and hypocretin-1 CSF contents in HD patients, controls or the combined group (all  $p > 0.11$ ). The CSF contents of hypocretin-1 was not different between HD patients and controls (HD: 481 pg/ml (422 – 536); controls: 549 pg/ml (409 – 631);  $p = 0.306$ , Figure 4), nor was there a significant correlation between the hypocretin cell counts and CSF levels in the 8 subjects (7 HD patients and 1 control) in whom both measurements were available ( $r = -0.238$ ;  $p = 0.570$ ). There were



no significant correlations between CSF hypocretin-1 levels and other (clinical) disease parameters (Table 3).

**Table 3. Spearman's  $\rho$  correlations (p-values) between post-mortem findings and other (clinical) disease parameters in HD patients.** The only significant correlation was between the prefrontal cortex Hcrt-1 levels and Vonsattel et al.'s grade of neuropathological disease severity. Trends were visible for the relations between Hcrt-1 cell number and age of onset and between MCH cell number and disease duration.

	Age at death	Age of onset	Disease duration	Grade	CAG repeat no.
Hcrt-1 cell no.	0.452 (0.260)	0.643 (0.086)	-0.096 (0.820)	-0.482 (0.227)	-0.429 (0.337)
MCH cell no.	-0.500 (0.391)	-0.200 (0.747)	-0.821 (0.089)	-0.700 (0.188)	0.300 (0.624)
Ventricular CSF Hcrt-1 levels	-0.607 (0.148)	-0.607 (0.148)	-0.436 (0.328)	-0.090 (0.848)	0.571 (0.180)
Prefrontal cortex Hcrt-1 levels	0.078 (0.760)	-0.417 (0.265)	0.192 (0.620)	-0.666 (0.004)*	-0.179 (0.476)

\* Correlation is significant at the 0.01 level.

### *Hypocretin-1 concentration in prefrontal cortex*

The two groups did not differ with respect to gender, but the HD group was significantly younger ( $p = 0.034$ ) (Table 2). However, hypocretin-1 concentrations were not significantly correlated with age (either in HD patients, controls, or the combined groups (all  $p \geq 0.37$ )). Hypocretin-1 concentration in controls was 676.6 (467.5 – 883.9) pg/gram of wet brain tissue, which is comparable to previously reported values (28). Compared to controls mean hypocretin-1 cortical levels were 33% lower in adult HD patients (416.4 pg/g (295.8 – 629.4);  $p = 0.025$ ). Furthermore, the prefrontal hypocretin-1 levels in these patients were significantly associated with the Vonsattel et al's grades ( $r = -0.666$ ,  $p = 0.004$ ), but not with other (clinical) disease parameters (Table 3). The patient with infantile HD had the highest levels of cortical hypocretin among all the HD patients studied (Table 2). Since the prefrontal tissues belonged to subjects whose hypocretin cell counts were unavailable, we could not relate the prefrontal cortex levels of hypocretin-1 to the hypocretin cell counts.

### *Neuronal intranuclear and cytoplasmic inclusions in HD hypothalami*


N-terminal huntingtin-positive neuronal intranuclear and cytoplasmic inclusions were observed in all HD hypothalami (Figure 5). Cytoplasmic inclusions were far more abundant than intranuclear inclusions which were seen only sporadically. Intranuclear inclusions were most consistently observed in the neurons of the tuberomammillary nucleus. The HD inclusions were not uniformly distributed among the various hypothalamic and adjacent structures (Table 4). Only in relatively few patients cytoplasmic inclusions were present in the most rostral hypothalamic structures (i.e. the suprachiasmatic, the supraoptic, and the paraventricular nuclei), while intranuclear inclusions could not be detected at all in these areas.

**Table 4. Neuronal inclusions in nuclei of HD hypothalami and adjacent regions.**


Type	SCN		SON		PVN		DBB/ NBM		INF		VMN		DMN		LH/ PFA		NTL		TMN		SMA	
	C	I	C	I	C	I	C	I	C	I	C	I	C	I	C	I	C	I	C	I	C	I
HD-1	-	-	+	-	+	-	+	-	+	-	+	-	+	-	+	+	+	-	+	+	+	-
HD-2	-	-	-	-	-	-	+	-	+	+	+	-	+	-	+	+	+	-	+	-	+	-
HD-3	+	-	+	-	+	-	+	-	+	-	+	-	+	-	+	-	+	-	+	+	+	-
HD-4	-	-	-	-	+	-	+	-	+	-	+	-	+	-	+	-	-	-	+	+	+	-
HD-5	+	-	-	-	-	-	+	-	+	-	+	-	+	-	+	-	+	-	+	+	+	-
HD-6	-	-	-	-	+	-	+	-	+	-	+	-	+	-	+	-	+	-	+	-	+	-
HD-7	+	-	+	-	-	-	+	+	+	+	+	+	+	-	+	-	+	+	+	+	+	-
HD-8	+	-	+	-	-	-	+	+	+	+	+	+	+	-	+	-	+	+	+	+	+	-
% patients	50	0	50	0	63	0	100	25	100	25	100	13	100	0	100	25	75	13	100	75	100	0

Legend: Type = type of neuronal inclusions; C = cytoplasmic inclusions (i.e. inclusions in dystrophic neurites); I = intranuclear inclusions; - = inclusions absent; + = inclusions present. The last row indicates, per structure, the percentage of HD patients who had neuronal inclusions of the specified type. SCN, suprachiasmatic nucleus; SON, supraoptic nucleus; PVN, paraventricular nucleus; INF, infundibular nucleus; DBB, diagonal band of Broca; NBM, nucleus basalis of Meynert; VMN, ventromedial nucleus; DMN, dorsomedial nucleus; LH, lateral hypothalamus; PFA, perifornical area; NTL, lateral tuberal nucleus; TMN, tuberomamillary nucleus; SMA, supramamillary area.


**Figure 3.** The total numbers of hypocretin-1 and MCH IR neurons in the lateral hypothalamus of control subjects and HD patients. The total number of hypocretin-1 IR neurons is significantly decreased in HD, while there is only a trend towards a reduction in the total number of MCH IR neurons (MWU-test:  $n = 16$ ,  $p = 0.015$  for Hcrt-1 and  $n = 11$ ,  $p = 0.100$  for MCH). Outliers (defined as data points which lie 1.5 times the interquartile range below the first or above the third quartile) are symbolized by 'o'. Hcrt-1, hypocretin-1.



**Figure 4.** Compared to controls, hypocretin-1 levels were significantly lower in the prefrontal cortex of HD patients (MWU-test:  $p = 0.025$ ), but not in their CSF (MWU-test:  $p = 0.306$ ). Hcrt-1, hypocretin-1.



**Figure 5.** Examples of neuronal intranuclear (arrow) and cytoplasmic (arrowheads) inclusions of mutant huntingtin in the tuberomammillary nucleus of one HD patient (#HD-7; obj. ×60 oil).



## DISCUSSION

In this study, we demonstrate a significant reduction by about 30% in the total number of hypocretin-1 neurons in the lateral hypothalamus of HD patients. This decrease appears to be relatively specific as the total number of MCH neurons was not significantly altered. Hypocretin-1 levels in the prefrontal cortex were reduced to the same extent, but ventricular CSF levels were unchanged. Furthermore, we describe the distribution of intranuclear and cytoplasmic inclusions of mutant huntingtin in the lateral hypothalamus and various other hypothalamic and adjacent structures in patients with HD.

Recently the density of hypocretin-1 neurons was assessed in single coronal sections from the lateral hypothalamus of HD patients and found to be decreased.<sup>27</sup> However, cell density is subject to substantial variation depending on both the rostro-caudal level of the sections (Figure 2) and the cutting direction. Therefore, in this study we systematically counted the *total* number of hypocretin-1 expressing neurons and were able to unequivocally confirm a significant but moderate decrease in the number of these neurons in HD patients. A positive trend was also visible for the relation between hypocretin-1 cell number and age of onset in HD patients paralleling findings by Kremer et al.<sup>21</sup> who found an association between neuronal numbers in the lateral tuberal nucleus and age of onset in HD.

We corroborated the specificity of the reduction in hypocretin-1 neuronal numbers by assessing the total number of MCH neurons as well. Since the reduction in hypocretin-1 neuronal numbers was more pronounced than that in MCH neuronal numbers, hypocretin neurons appear to be more vulnerable to the pathogenic mechanisms underlying HD. Interestingly, a recent study in rat hypothalamic slice cultures showed that 24-hours of incubation with N-methyl-D-aspartate (NMDA) resulted in a marked decrease in the number of hypocretin-1 neurons, whereas MCH neurons in the same cultures were relatively spared.<sup>19</sup> Moreover, examinations of the effects of several endogenous glutamate receptor agonists highlighted quinolinic acid as an endogenous excitotoxin that could cause selective loss of hypocretin-1 neurons as compared to MCH neurons by activating NMDA receptors.<sup>19</sup> Therefore, NMDA receptor-mediated excitotoxicity could be involved in the greater susceptibility of hypocretin-1 neurons in HD patients, a pathomechanism that has also been proposed for the massive neuronal loss in the lateral tuberal nucleus of these patients.<sup>21</sup>

To further assess hypocretin neurotransmission in HD, we also examined hypocretin-1 contents in the prefrontal cortex and ventricular CSF. Whereas the mean levels of hypocretin-1 were about 30% lower in the

prefrontal cortex of HD subjects and correlated with Vonsattel et al's grades, ventricular CSF hypocretin-1 contents did not differ between patients and controls. The latter finding is in accordance with four recent papers that reported normal hypocretin-1 concentrations in the CSF of HD patients.<sup>3,4,11,24</sup> The apparent discrepancy between the findings in the CSF and those in the hypothalamus and the prefrontal cortex of HD patients could be accounted for by the fact that a mean reduction of approximately 30% in the number of hypocretin-1 neurons is probably not large enough to be reflected in the CSF.<sup>3,11,24</sup> This assumption is supported by the fact that a reduction by half in the number of hypocretin neurons in PD patients only causes a 25% decrease in hypocretin-1 levels in the ventricular CSF.<sup>10</sup> Accordingly, rat studies indicate that a 73% decline in hypocretin neuronal numbers is needed to decrease CSF hypocretin-1 levels by half.<sup>12</sup> Yet another possibility is impaired clearance of hypocretin-1 from the CSF in HD.

So far, hypocretin signalling has been studied in two animal models of HD. The R6/2 mouse model is reported to have a loss of more than 70% in both hypocretin-1 expressing neurons and hypocretin-1 CSF levels, whereas the YAC128 mouse model exhibits a reduction of 10% in the number of hypocretin-1 neurons. Moreover, R6/2 mice are reported to have a loss of almost 40% in the number of MCH expressing neurons while their hypothalamic MCH levels are reduced by nearly 60%.<sup>39</sup> The discrepancy between our findings and those from these transgenic mice could be accounted for by the existence of several confounding variables. First, these transgenic mouse models have very large CAG repeat expansions (> 120 repeats) and resemble juvenile HD more than the adult form of the disease.<sup>25</sup> An intriguing possibility is thus that juvenile HD patients might indeed exhibit more extensive pathology of the hypocretin system. In this study, we could measure hypocretin-1 levels in the prefrontal cortex of only one juvenile HD patient (Table 2). Surprisingly, this case appeared to have the highest levels of cortical hypocretin among all the HD patients studied. This finding may, however, be due to the stronger cortical atrophy that accompanies the juvenile variant of HD compared to the adult form of the disease.<sup>35</sup> Second, the mild reduction in hypocretin in the YAC128 mice may be due to the fact that these mice, unlike the R6/2 mice and several human patients, were not (close to) end stage at the time of assessment (i.e. 12 months). Thus, several variables may confound the comparisons between various animal models and the human condition and should, therefore, be taken into consideration when comparing animal and human data.

Hypocretin deficiency is the primary pathophysiological cause of narcolepsy, a sleep-wake disorder characterized by excessive daytime sleepiness and REM-sleep dissociation phenomena such as cataplexy, i.e. a sudden weakening of posture muscle tone usually triggered by emotion.<sup>26</sup> Although R6/2 mice exhibit episodes of behavioural arrest closely resembling those seen in *hypocretin* knock-out mice and transgenic mice with specific ablation of hypocretin-containing neurons,<sup>6,15</sup> it remains to be shown whether the modest decrease of hypocretin-1 signalling in adult HD patients could contribute to clinical symptoms, particularly sleep disturbances.<sup>42</sup> Unfortunately, due to the retrospective nature of our study we could not relate our post-mortem findings to clinical signs and symptoms. This stresses the need for systematic post-mortem brain tissue collection of clinically well-documented patients for future neuropathological studies.

In this report we also present an estimation of the total number of MCH neurons in the human brain and their

relative distribution with respect to hypocretin-1 neurons. Our results confirm those from a recent study<sup>38</sup> and suggest that MCH neurons are indeed more abundant in the human hypothalamus and have a wider rostro-caudal distribution than hypocretin-1 neurons, which is also in accordance with findings in rodents.<sup>1,37</sup> Even though MCH and hypocretin-1 neurons start to appear at about the same level rostrally, MCH neurons are relatively more abundant in the posterior hypothalamus. Whether this finding could be accounted for by the existence of several distinct MCH subpopulations along the rostro-caudal axis as opposed to a more homogenous hypocretin population<sup>1,37</sup> remains to be elucidated. As we could not find a clear reduction in the number of MCH neurons in HD patients, alterations in MCH levels are unlikely to have clinical implications in HD.

In this study we have assessed neuronal numbers by counting immunopositive neurons by means of a technique that has been validated and applied previously.<sup>9,10,38</sup> It should be stressed that it is in principle impossible to distinguish the loss of an immunocytochemical neuronal marker from the loss of the neurons in a heterogeneous and anatomically loosely defined brain structure such as the lateral hypothalamus.

Interestingly, neuronal intranuclear and cytoplasmic inclusions were not uniformly present in various hypothalamic and adjacent structures in HD patients. This finding may indicate that various hypothalamic nuclei are differentially affected by inclusion formation despite their close anatomical juxtaposition in the hypothalamus. Elucidation of the underlying mechanisms of this heterogeneity may lead to better understanding of why certain neuronal populations are more susceptible to HD pathology than others.

In conclusion, we found a specific reduction by about 30% in hypocretin signalling in patients with HD. It remains to be shown whether this moderate decrease in hypocretin signalling could contribute to clinical symptoms. As MCH cell number was not clearly affected in HD patients, alterations in MCH neurotransmission are unlikely to have clinical effects in HD.

## ACKNOWLEDGEMENTS

The authors are greatly indebted to the following persons for their invaluable support: R. Balesar, B. Fisser, M.A. Hofman, J.J. van Heerikhuizen, J. van Pelt, I. Huitinga, M. Kooreman, I.M. Hegeman-Klein, C. Welling-Graafland, W. Verweij and H. Belier-Lakeman. N.A. Aziz and S. Overeem were supported by The Netherlands Organisation for Scientific Research (grants #017.003.098 and #916.56.103, respectively).

## REFERENCES

1. Amiot, C., Brischoux, F., Colard, C., La Roche, A., Fellmann, D., and Risold, P. Y. Hypocretin/orexin-containing neurons are produced in one sharp peak in the developing ventral diencephalon. *Eur.J.Neurosci.* 2005; 22: 531-534.
2. Aziz, N. A., Swaab, D. F., Pijl, H., and Roos, R. A. Hypothalamic dysfunction and neuroendocrine and metabolic alterations in Huntington disease: clinical consequences and therapeutic



implications. *Rev Neurosci* 2007; 18: 223-252.

3. Baumann, C. R., Hersberger, M., and Bassetti, C. L. Hypocretin-1 (orexin A) levels are normal in Huntington's disease. *J.Neurol.* 2006; 253: 1232-1233.
4. Björkqvist, M., Petersen, A., Nielsen, J., Ecker, D., Mulder, H., Hayden, M., Landwehrmeyer, B., Brundin, P., and Leavitt, B. Cerebrospinal fluid levels of orexin-A are not a clinically useful biomarker for Huntington disease. *Clin.Genet.* 2006; 70: 78-79.
5. Brundin, L., Petersen, A., Björkqvist, M., and Traskman-Bendz, L. Orexin and psychiatric symptoms in suicide attempters. *J.Affect.Disord.* 2007; 100: 259-263.
6. Chemelli, R. M., Willie, J. T., Sinton, C. M., Elmquist, J. K., Scammell, T., Lee, C., Richardson, J. A., Williams, S. C., Xiong, Y., Kisanuki, Y., Fitch, T. E., Nakazato, M., Hammer, R. E., Saper, C. B., and Yanagisawa, M. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. 1999; *Cell* 98: 437-451.
7. Chen, C. T., Dun, S. L., Kwok, E. H., Dun, N. J., and Chang, J. K. Orexin A-like immunoreactivity in the rat brain. *Neurosci Lett.* 1999; 260: 161-164.
8. Difiglia, M., Sapp, E., Chase, K. O., Davies, S. W., Bates, G. P., Vonsattel, J. P., and Aronin, N. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. *Science* 1997; 277: 1990-1993.
9. Fronczek, R., Lammers, G. J., Balesar, R., Unmehopa, U. A., and Swaab, D. F. The number of hypothalamic hypocretin (orexin) neurons is not affected in Prader-Willi syndrome. *J.Clin.Endocrinol.Metab* 2005; 90: 5466-5470.
10. Fronczek, R., Overeem, S., Lee, S. Y., Hegeman, I. M., van Pelt, J., Van Duinen, S. G., Lammers, G. J., and Swaab, D. F. Hypocretin (orexin) loss in Parkinson's disease. *Brain* 2007; 130: 1577-1585.
11. Gaus, S. E., Lin, L., and Mignot, E. CSF hypocretin levels are normal in Huntington's disease patients. *Sleep* 2005; 28: 1607-1608.
12. Gerashchenko, D., Murillo-Rodriguez, E., Lin, L., Xu, M., Hallett, L., Nishino, S., Mignot, E., and Shiromani, P. J. Relationship between CSF hypocretin levels and hypocretin neuronal loss. *Exp.Neurol.* 2003; 184: 1010-1016.
13. Goldstone, A. P., Unmehopa, U. A., Bloom, S. R., and Swaab, D. F. Hypothalamic NPY and agouti-related protein are increased in human illness but not in Prader-Willi syndrome and other obese subjects. *J.Clin.Endocrinol.Metab* 2002; 87: 927-937.
14. Goldstone, A. P., Unmehopa, U. A., and Swaab, D. F. Hypothalamic growth hormone-releasing hormone (GHRH) cell number is increased in human illness, but is not reduced in Prader-Willi syndrome or obesity. *Clin.Endocrinol.(Oxf)* 2003; 58: 743-755.
15. Hara, J., Beuckmann, C. T., Nambu, T., Willie, J. T., Chemelli, R. M., Sinton, C. M., Sugiyama, F., Yagami, K., Goto, K., Yanagisawa, M., and Sakurai, T. Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. *Neuron* 2001; 30: 345-354.
16. Harper, P. *Huntington's Disease*. W.B. Saunders Company Ltd., London, 1996.
17. Kalra, S. P., Dube, M. G., Pu, S., Xu, B., Horvath, T. L., and Kalra, P. S. Interacting appetite-regulating

pathways in the hypothalamic regulation of body weight. *Endocr.Rev.* 1999; 20: 68-100.

18. Kassubek, J., Juengling, F. D., Kioschies, T., Henkel, K., Karitzky, J., Kramer, B., Ecker, D., Andrich, J., Saft, C., Kraus, P., Aschoff, A. J., Ludolph, A. C., and Landwehrmeyer, G. B. Topography of cerebral atrophy in early Huntington's disease: a voxel based morphometric MRI study. *J.Neurol.Neurosurg.Psychiatry* 2004; 75: 213-220.
19. Katsuki, H. and Akaike, A. Excitotoxic degeneration of hypothalamic orexin neurons in slice culture. *Neurobiol.Dis.* 2004; 15: 61-69.
20. Kremer, H. P., Roos, R. A., Dingjan, G., Marani, E., and Bots, G. T. Atrophy of the hypothalamic lateral tuberal nucleus in Huntington's disease. *J.Neuropathol.Exp.Neurol.* 1990; 49: 371-382.
21. Kremer, H. P., Roos, R. A., Dingjan, G. M., Bots, G. T., Bruyn, G. W., and Hofman, M. A. The hypothalamic lateral tuberal nucleus and the characteristics of neuronal loss in Huntington's disease. *Neurosci.Lett.* 1991; 132: 101-104.
22. Loader, C. Local regression and likelihood. Springer-Verlag, New York, 1999.
23. Mardia, K. V. Statistics of Directional Data. Academic Press, New York, 1972.
24. Meier, A., Mollenhauer, B., Cohrs, S., Rodenbeck, A., Jordan, W., Meller, J., and Otto, M. Normal hypocretin-1 (orexin-A) levels in the cerebrospinal fluid of patients with Huntington's disease. *Brain Res.* 2005; 1063: 201-203.
25. Menalled, L. B. and Chesselet, M. F. Mouse models of Huntington's disease. *Trends Pharmacol.Sci.* 2002; 23: 32-39.
26. Overeem, S., Scammell, T. E., and Lammers, G. J. Hypocretin/orexin and sleep: implications for the pathophysiology and diagnosis of narcolepsy. *Curr.Opin.Neurol.* 2002; 15: 739-745.
27. Petersen, A., Gil, J., Maat-Schieman, M. L., Björkqvist, M., Tanila, H., Araujo, I. M., Smith, R., Popovic, N., Wierup, N., Norlen, P., Li, J. Y., Roos, R. A., Sundler, F., Mulder, H., and Brundin, P. Orexin loss in Huntington's disease. *Hum.Mol.Genet.* 2005; 14: 39-47.
28. Peyron, C., Faraco, J., Rogers, W., Ripley, B., Overeem, S., Charnay, Y., Nevsimalova, S., Aldrich, M., Reynolds, D., Albin, R., Li, R., Hungs, M., Pedrazzoli, M., Padigaru, M., Kucherlapati, M., Fan, J., Maki, R., Lammers, G. J., Bouras, C., Kucherlapati, R., Nishino, S., and Mignot, E. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. *Nat.Med.* 2000; 6: 991-997.
29. Peyron, C., Tighe, D. K., van den Pol, A. N., de Lecea, L., Heller, H. C., Sutcliffe, J. G., and Kilduff, T. S. Neurons containing hypocretin (orexin) project to multiple neuronal systems. *J.Neurosci.* 1998; 18: 9996-10015.
30. Pissios, P., Bradley, R. L., and Maratos-Flier, E. Expanding the scales: The multiple roles of MCH in regulating energy balance and other biological functions. *Endocr.Rev.* 2006; 27: 606-620.
31. Sakurai, T., Amemiya, A., Ishii, M., Matsuzaki, I., Chemelli, R. M., Tanaka, H., Williams, S. C., Richardson, J. A., Kozlowski, G. P., Wilson, S., Arch, J. R., Buckingham, R. E., Haynes, A. C., Carr, S. A., Annan, R. S., McNulty, D. E., Liu, W. S., Terrett, J. A., Elshourbagy, N. A., Bergsma, D. J., and Yanagisawa, M. Orexins and orexin receptors: a family of

hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. *Cell* 1998; 92: 573-585.

32. Salomon, R. M., Ripley, B., Kennedy, J. S., Johnson, B., Schmidt, D., Zeitzer, J. M., Nishino, S., and Mignot, E. Diurnal variation of cerebrospinal fluid hypocretin-1 (Orexin-A) levels in control and depressed subjects. *Biol.Psychiatry* 2003; 54: 96-104.
33. Shimada, M., Tritos, N. A., Lowell, B. B., Flier, J. S., and Maratos-Flier, E. Mice lacking melanin-concentrating hormone are hypophagic and lean. *Nature* 1998; 396: 670-674.
34. Shimazaki, T., Yoshimizu, T., and Chaki, S. Melanin-Concentrating Hormone MCH(1) Receptor Antagonists : A Potential New Approach to the Treatment of Depression and Anxiety Disorders. *CNS.Drugs* 2006; 20: 801-811.
35. Squitieri, F., Frati, L., Ciarmiello, A., Lastoria, S., and Quarrell, O. Juvenile Huntington's disease: does a dosage-effect pathogenic mechanism differ from the classical adult disease? *Mech. Ageing Dev.* 2006; 127: 208-212.
36. Swaab, D. F. The human hypothalamus: basic and clinical aspects, part I: nuclei of the human hypothalamus. *Handbook of Clinical Neurology*. Vol. 79. Series Editors: Aminoff, M. J., Boller, F., and Swaab, D. F. (Amsterdam, The Netherlands: Elsevier), 2003.
37. Swanson, L. W., Sanchez-Watts, G., and Watts, A. G. Comparison of melanin-concentrating hormone and hypocretin/orexin mRNA expression patterns in a new parceling scheme of the lateral hypothalamic zone. *Neurosci Lett.* 2005; 387: 80-84.
38. Thannickal, T. C., Lai, Y. Y., and Siegel, J. M. Hypocretin (orexin) cell loss in Parkinson's disease. *Brain* 2007; 130: 1586-1595.
39. Van der Burg, J. M. M., Bacos, K., Wood, N. I., Lindqvist, A., Wierup, N., Woodman, B., Wamsteeker, J. I., Smith, R., Deierborg, T., Kuhar, M. J., Bates, G. P., Mulder, H., Erlanson-Albertsson, C., Morton, A. J., Brundin, P., Petersen, A., and Björkqvist, M. Increased metabolism in the R6/2 mouse model of Huntington's disease. *Neurobiol.Dis.* 2008; 29(1): 41-51.
40. Van der Sluis, P. J., Pool, C. W., and Sluiter, A. A. Press-blotting on gelatin-coated nitrocellulose membranes. A method for sensitive quantitative immunodetection of peptides after gel isoelectric focusing. *J.Immunol.Methods* 1987; 104: 65-71.
41. Vonsattel, J. P., Myers, R. H., Stevens, T. J., Ferrante, R. J., Bird, E. D., and Richardson, E. P., Jr. Neuropathological classification of Huntington's disease. *J.Neuropathol.Exp.Neurol.* 1985; 44: 559-577.
42. Wiegand, M., Moller, A. A., Lauer, C. J., Stolz, S., Schreiber, W., Dose, M., and Krieg, J. C. Nocturnal sleep in Huntington's disease. *J.Neurol.* 1991; 238: 203-208.
43. Willie, J. T., Chemelli, R. M., Sinton, C. M., and Yanagisawa, M. To eat or to sleep? Orexin in the regulation of feeding and wakefulness. *Annu.Rev.Neurosci.* 2001; 24: 429-458.